Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
- Date
- Aug 10, 2026
- Company
- Fresenius Kabi
- Brand
- Fresenius Kabi
- Product
- Tyenne Injection 400 mg/20 mL vial
- Reason
- Due to Presence of Glass Particles
- Hazard
- Other
- Source
- FDA
How to identify the product
- August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level.
- Tyenne (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL was distributed nationwide to wholesalers, distributors and direct customers.
- Fresenius Kabi is notifying its distributors and customers by letter and is arranging for return of the recalled product.
- If health care facilities have any of the affected lot, they are to immediately discontinue distributing, dispensing, or using the lot and return all units to Fresenius Kabi.
- Distributors are instructed to immediately notify their customers that have been shipped or may have been shipped, the product involved in this recall.
Product photos are on the official FDA page.
Facts are taken from the official notice. If anything here differs from it, the official notice is correct.